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Abstract
Purpose: To describe a patient with Thygeson's superficial punctate keratitis successfully treated
with long-term cyclosporin A.
Case presentation: A 15-year-old boy presented with long-term ocular symptoms of foreign
body sensation, burning, irritation, tearing, and transient photophobia. One year's treatment with
steroidal agents had led to only partial improvement. Clinical and laboratory evaluation yielded a
diagnosis of Thygeson's superficial punctate keratitis. Treatment with 0.5% topical cyclosporin A
for the last 4.5 years has been associated with symptom resolution and corneal clearing, without
side effects.
Conclusion: Topical cyclosporin A seems to effective and safe for the treatment of Thygeson's
superficial punctuate keratitis and should be considered in selective cases when topical steroids fail
or in there is a high risk of complications from long-term steroid treatment. Considering the
chronicity of Thygeson's superficial punctate keratitis, further prospective studies of long-term
cyclosporine A treatment are needed.
Introduction
In 1950, Thygeson was the first to describe the clinical
entity of transient, bilateral, coarse corneal epithelial
opacities, without associated stromal involvement or cor-
neal edema, which was later termed Thygeson's superficial
punctate keratitis (TSPK) [1]. TSPK usually occurs in the
second to third decade of life, though patients of all ages
can be affected. It has a chronic course characterized by
exacerbations and remissions. The duration of the disease
ranges from 1 month to 24 years; some cases of a longer
course of up to 41 years have been described as well [2].
The management of TSPK varies with disease severity.
During quiescent periods with minimal irritation, simple
lubricating drops or no treatment is sufficient [3]. During
acute exacerbations, topical corticosteroids have been
found to decrease signs and symptoms [1]. Therapeutic
contact lenses can be used to reduce the irritation in more
symptomatic patients [3].
We describe a patient with TSPK that responded only par-
tially to long-term corticosteroids. A switch to topical
cyclosporin A was associated with very favorable results,
without any side effects
Case presentation
A 15-year-old otherwise healthy boy presented to the Cor-
nea Service at Rabin Medical Center complaining of for-
eign body sensation, burning, tearing, and irritation in
both eyes accompanied by mild transient photophobia.
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One year's treatment with topical steroids and various
antibiotics had been associated with only partial remis-
sion with intermittent exacerbations. Clinical examina-
tion showed a best-corrected visual acuity (BCVA) of 6/9
OU with correction. Intraocular pressure was 15 mmHg in
both eyes. No pathologic findings were noted in the eye-
lids. There was only trace conjunctival injection. On slit-
lamp examination, discrete, centrally located, slightly ele-
vated, grayish-white corneal subepithelial opacities were
detected, with a granular texture bilaterally (Figure 1).
They did not stain with fluorescent dye. The anterior
chambers and vitreous were clear, with no inflammatory
reaction, cells, flare or any kind of opacification. A diagno-
sis of TSPK was made on the basis of the clinical appear-
ance of bilateral superficial punctuate epithelial
keratopathy with minimal conjunctival reaction, the chro-
nicity of the disease with remissions and exacerbations,
and the partial response to topical corticosteroids. The
patient did not agree to use soft contact lenses, and he was
already receiving topical corticosteroids for a long period.
Therefore, we decided on a trial with topical cyclosporin
A. After receiving consent from the patient and his family,
the patient was prescribed 0.5% cyclosporin A drops in
castor oil 3 times a day.
Over the next 3 months, there was a slow but noticeable
improvement in clinical symptoms. On follow-up slit-
lamp examination, the corneal subepithelial opacities had
cleared almost completely, and the minimal conjunctival
injection had disappeared. Continued treatment for the
next 4 years led to total regression of the disease. Every
attempt to taper the cyclosporin A treatment resulted in a
reappearance of symptoms and of corneal opacities.
At the most recent follow-up visit, 4.5 years after presenta-
tion, the patient was still applying cyclosporin A drops 3
times daily. He had no symptoms. Visual acuity was 6/6
in both eyes. There was no conjunctival inflammation,
and the corneas were clear without opacification. (Figure
2) Endothelial cell count was within normal range in both
eyes.
Discussion
We describe a patient with TSPK treated with topical
cyclosporin A drops for 4.5 years with excellent results. To
our knowledge, this is the longest course of topical
cyclosporin A treatment for TSPK reported in the litera-
ture.
Cyclosporin A is a potent immunomodulator that was
reported to be helpful as a primary or adjunctive therapy
in the treatment of keratoconjunctivitis sicca, vernal con-
junctivitis, atopic conjunctivitis, and superior limbic kera-
toconjunctivitis [4]. When administered systemically, it
may be associated with such adverse effects as acute and
chronic nephrotoxicity, neurotoxicity, hypertension, and
new-onset diabetes [5]. However, in accordance with the
low cyclosporin A concentrations found in blood and in
tissues other than those at the ocular surface, no systemic
adverse effects were associated with topical ophthalmic
cyclosporin A treatment [6]. In phase 3 clinical trials of
0.05% and 0.1% ophthalmic emulsions of cyclosporin for
the treatment of dry eye disease, the most common treat-
ment-related adverse events were burning eye, stinging
eye, and conjunctival hyperemia. The safety profile of
cyclosporin treatment was excellent [7,8].
The effectiveness and safety of cyclosporin specifically for
the treatment of TSPK has been tested so far in two pro-
Left cornea before cyclosporin A treatment Figure 1
Left cornea before cyclosporin A treatment. Note the 
slightly elevated, grayish-white subepithelial opacities. Clinical 
appearance was similar in the right eye.
Left cornea after cyclosporin A treatment Figure 2
Left cornea after cyclosporin A treatment. Note the 
clear cornea, with full resolution of the opacities with no 
sequelae. The clinical appearance was similar in right eye.Publish with BioMed Central    and   every 
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spective studies. Both showed that 2% cyclosporin A treat-
ment led to suppression of the epithelial and
subepithelial opacities and satisfactory control of the con-
dition. The authors recommended it as a safe alternative
to corticosteroids [9,10].
Topical corticosteroids remain the mainstay of treatment
for TSPK because of their widespread availability and
effectiveness. However, their long-term use is known to
lead to side effects. Furthermore, one study found that
prolongation of the course of TPSK may be secondary to
the introduction of corticosteroids [2]. Therefore, consid-
ering the relatively young age of onset of TPSK and the
consequent need for prolonged therapy, together with the
apparent effectiveness and minor, if any, side effects of
cyclosporin A, we suggest that topical cyclosporin A can be
used as first-line therapy in selective cases of Thygeson's
superficial punctuate keratitis when topical steroids fail or
in the presence of a high risk of complications from long-
term steroid treatment. Further prospective studies of
long-term cyclosporin A treatment in this setting are
needed.
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